PBYI

PUMA BIOTECHNOLOGY, INC. - 10-Q Summary (Q1 2026)

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Puma Biotechnology, Inc. is a biopharmaceutical company focused on the commercialization of NERLYNX® (neratinib) for HER2-positive breast cancer and the global development of alisertib, an Aurora Kinase A inhibitor. The company operates as a single reporting segment and is classified as an accelerated filer and smaller reporting company.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. Net loss per share was $(0.07) for Q1 2026 compared to $0.06 income in Q1 2025.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by approximately $1.2 million (2.6%) primarily due to a $1.1 million decrease in net product revenue. This was driven by higher deductions for variable consideration (government chargebacks and payor mix), partially offset by price increases.
• Operating Loss: The company reported an operating loss of $3.8 million, compared to operating income of $4.0 million in the prior year. This shift was driven by a significant increase in Research and Development (R&D) expenses.
• R&D Expense Surge: R&D expenses increased by $5.9 million (42.8%) to $19.8 million, primarily due to a $5.2 million increase in clinical trial expenses related to the advancement of alisertib studies.
• Debt Reduction: The current portion of long-term debt decreased by $11.2 million as the company continued scheduled principal payments on its Athyrium Notes.
• Strong Operating Cash Flow: Net cash provided by operating activities improved significantly to $15.4 million, largely due to a $27.3 million decrease in accounts receivable (royalty receipts from China) and a $3.1 million increase in accounts payable.

Guidance, Outlook, and Risks

• Liquidity: Management believes existing cash, cash equivalents, and marketable securities (totaling ~$101.5 million) combined with expected product sales and sub-license payments are sufficient to fund operations for at least one year.
• Debt Repayment: In a subsequent event on May 4, 2026, the company prepaid the remaining $11.5 million principal and fees on its Athyrium Notes, terminating all obligations under the agreement ahead of the July 2026 maturity date.
• Legal Proceedings:
  • AstraZeneca Litigation: A jury previously awarded $107.5 million in damages for patent infringement. However, the District Court later ruled the patents invalid on specific claim limitations. The case is currently on appeal with oral arguments scheduled for May 7, 2026.
  • China Patent Litigation: The company has faced multiple ANDA filings by generic manufacturers (Acebright, Aosaikang, Convalife, Kelun, Demai). Several generic versions have received NMPA approval in China, and the company has lost recent infringement suits against Acebright.
  • European Patent Opposition: Oppositions to European Patent EP3000467 were upheld as amended at the first instance, but appeals are pending.
• Tariff Risk: The company is reviewing the impact of new U.S. tariffs on imported patented pharmaceutical products announced in April 2026.

Investor Verification Checklist

• Verify the status and potential financial impact of the AstraZeneca patent appeal scheduled for May 2026, given the conflicting jury verdict and court ruling on patent validity.
• Monitor the commercial impact of generic NERLYNX approvals in China (Acebright, Aosaikang, Convalife, Kelun, Demai) on future royalty revenue streams.
• Confirm the progress of alisertib clinical trials (ALISCA-Lung1 and ALISCA-Breast1) to justify the 43% increase in R&D spending.
• Review the post-payment debt covenant status following the May 2026 full repayment of the Athyrium Notes to ensure no lingering financial restrictions.
• Assess the potential impact of new U.S. pharmaceutical tariffs on the cost of goods sold and gross margins.